XNCR

Xencor, Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Monrovia, California. The company went public in December 2013 and has established itself as a leader in engineered antibody therapeutics. Xencor specializes in developing innovative treatments for cancer and autoimmune diseases using its proprietary XmAb protein engineering platform, which creates enhanced monoclonal antibodies and cytokines with improved therapeutic properties compared to conventional treatments.